New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 28, 2013
16:07 EDTCTICCell Therapeutics sees FY13 loss from operations $60M-$65M
For 2013, loss from operations is expected to be approximately $60M-$65M, excluding non-cash stock-based compensation expense. The projected decrease in 2013 loss from operations, compared to 2012, primarily relates to expected changes in contribution margin from PIXUVRI commercial operations, as it intends to operate the commercial business with a net positive contribution; SG&A expenses, including sales and marketing expenses to drive sales of PIXUVRI; and R&D expenses.
News For CTIC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 29, 2014
16:18 EDTCTICCTI BioPharma raises FY14 operating loss view to $66M-$71M from $45M-$50M
As a result of the stock issuance in the transaction described above with Chroma resulting in an expense recognition of approximately $21M, CTI has revised its financial guidance such that non-GAAP operating loss for 2014 is now expected to range from approximately $66M-$71M rather than $45M-$50M as previously expected, which excludes non-cash share-based compensation expense.
16:16 EDTCTICCTI BioPharma reports Q3 EPS 3c, consensus (3c)
Reports Q3 revenue $39.53M, consensus $24.3M.
October 27, 2014
05:14 EDTCTICCTI BioPharma acquires exclusive worldwide license to tosedostat
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use